A phase 3 clinical trial focused on patients with advanced breast cancer characterized by positive hormone receptors and negative for human epidermal growth factor receptor 2 (HER2), who had relapsed or progressed during or following treatment with aromatase inhibitors. The gene discussed is NR4A1; the disease is breast carcinoma.